葛根芩连丸治疗新型冠状病毒肺炎的临床研究  

Clinical study of Gegen Qinlian pill in treating COVID-19

作　　者：王林群[1] 李伟男[2,3,4] 黄威 周忠明 邓亚丽[2,3,4] 胡运莲 陶然[2,3,4] 左新河 冯毅[2,3,4] 陆定波 余昪昪[2,3,4] Wang Linqun;Li Weinan;Huang Wei;Zhou Zhouming;Deng Yali;Hu Yunlian;Tao Ran;Zuo Xinhe;Feng Yi;Lu Dingbo;Yu Bianbian(Hubei University of Chinese Medicine,Wuhan 430061,China;Hubei Provincial Hospital of TCM,Wuhan 430061,China;Affiliated Hospital of Hubei University of TCM,Wuhan 430061,China;Hubei Research Institute of TCM,Wuhan 430061,China;Wuhan Third Hospital,Wuhan 430060,China)

机构地区：[1]湖北中医药大学,武汉430061 [2]湖北省中医院,武汉430061 [3]湖北中医药大学附属医院,武汉430061 [4]湖北省中医药研究院,武汉430061 [5]武汉市第三医院,武汉430060

出　　处：《世界科学技术-中医药现代化》2020年第10期3509-3514,共6页Modernization of Traditional Chinese Medicine and Materia Medica-World Science and Technology

基　　金：湖北省科学技术厅新型肺炎应急科技攻关项目(2020FCA007):基于肺炎1号为主的中医药治疗新型冠状病毒肺炎的临床研究,负责人:巴元明。

摘　　要：目的探讨葛根芩连丸治疗新型冠状病毒肺炎(COVID-19)的临床疗效。方法选择2020年2月23日-3月15日湖北省中医院收治的COVID-19患者,最终共纳入118例,按治疗方法随机分为对照组60例与治疗组58例。对照组给予常规治疗,治疗组在对照组治疗的基础上加用葛根芩连丸口服,每天3次,每次1包。观察两组退热时间、核酸转阴时间、转重症率、死亡率、临床疗效及治疗前后症状积分、肺部CT的改变。结果两组患者治疗后发热、咳嗽、乏力等主要症状较治疗前显著改善(P<0.05)。治疗组在改善咳嗽、胸闷、恶心、呕吐、大便稀溏方面更为明显(P<0.05)。两组胃肠道症状积分和症状总积分较治疗前均明显降低(P<0.05),且治疗后两组间有显著性差异(P<0.05)。治疗组舌质、舌苔的改善比对照组更加明显(P>0.05)。治疗后,对照组白细胞计数、淋巴细胞绝对值与治疗前比较有显著性差异(P<0.05),且治疗后两组间有显著性差异(P<0.05)。治疗后两组hs-CRP明显降低(P<0.05),两组间有显著性差异(P<0.05)。两组退热时间无显著性差异(P>0.05)。两组新型冠状病毒核酸转阴时间有显著性差异(P<0.05)。对照组与治疗组肺部CT均较前好转,且无显著差异(P>0.05);两组患者在出院达标方面无明显差异,且均未出现无效、死亡以及向重型危重型转化等病例。治疗过程中未见不良反应,临床应用安全性良好。结论葛根芩连丸能积极改善COVID-19患者临床症状,对胃肠道症状有较好的治疗作用,使用安全可靠,值得在临床进一步推广。Objective To discuss the clinical efficacy of Gegen Qinlian pill in the treatment of COVID-19.Methods A total of 118 COVID-19 patients admitted to Hubei Provincial Hospital of TCM from February 23 to March 15, 2020 were selected, and randomly divided into a control group of 60 patients and a treatment group of 58 patients according to treatment methods. The control group was given routine treatment. In addition to the control group, the treatment group was given Gegen Qinlian pill orally, 3 times a day, 1 packet each time. The changes of antipyretic time, negative nucleic acid time, severe disease rate, mortality, clinical efficacy, symptom score and pulmonary CT before and after treatment were observed in both groups. Results The main symptoms of fever, cough and fatigue in the two groups after treatment were significantly improved(P< 0.05).In the treatment group, cough, chest tightness, nausea, vomiting and loose stool was improved significantly(P< 0.05). The gastrointestinal symptom score and total symptom score in both groups were significantly reduced after treatment(P< 0.05), and there was a significant difference between the two groups after treatment(P< 0.05). The improvement of tongue quality and tongue coating in the treatment group was more obvious than that in the control group(P >0.05). After treatment, the leukocyte count and lymphocyte absolute value of the control group were significantly different from those before treatment(P< 0.05), and there was a significant difference between the two groups after treatment(P< 0.05). After treatment, hS-CRP was significantly reduced in both groups(P< 0.05), and there was a significant difference between the two groups(P< 0.05). There was no significant difference in antipyretic time between the two groups(P >0.05). There was significant difference in the coronavirus negative nucleic acid time between the two groups(P< 0.05). Pulmonary CT of the two groups was improved compared with that before, and there was no significant difference(P >0.05). There was no si

关 键 词：葛根芩连丸 新型冠状病毒肺炎 临床研究 中医药 

分 类 号：R287[医药卫生—中药学]